For the fiscal year ending June 2027 Q1, consolidated net sales were 5,771 million yen (YoY -3.0%), and operating income was 1,113 million yen (YoY -17.7%). Sales declined in both the Active Pharmaceutical Ingredients (API) and Pharmaceuticals segments. Growth in results is expected in Q4. Foreign exchange effects slightly boosted operating income. Investment impact from the new factory and higher personnel expenses increased selling, general and administrative expenses, pressuring overall profits.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9273","jir_company_name":"Koa Shoji Holdings Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/9273-20261106-02.pdf","jir_short_summary":"For the fiscal year ending June 2027 Q1, consolidated net sales were 5,771 million yen (YoY -3.0%), and operating income was 1,113 million yen (YoY -17.7%). Sales declined in both the Active Pharmaceutical Ingredients (API) and Pharmaceuticals segments. Growth in results is expected in Q4. Foreign exchange effects slightly boosted operating income. Investment impact from the new factory and higher personnel expenses increased selling, general and administrative expenses, pressuring overall profits.","jir_summary":"### Performance Overview\nConsolidated net sales for the period were 5,771 million yen (YoY -3.0%). The cost of sales ratio rose to 69.3%, and the SG&A ratio rose to 11.4%. Operating income decreased to 1,113 million yen (YoY -17.7%). Sales fell in both the API and Pharmaceuticals segments due to factors including drug price revisions for key products. Costs associated with the start-up of the Zao No.2 Factory and rising personnel expenses also had an impact.\n\n### Outlook and Risks\nThe company expects sales and profits to expand in Q4 and states progress is generally on plan. Foreign exchange movements could slightly boost profits. However, attention is required for external factors such as the impact of drug price revisions and supplier production discontinuations.","jir_financial_highlights":"Net sales: 5,771 (YoY -3.0%)\nCost of sales: 4,001 (YoY -0.7%)\nGross profit: 1,769 (YoY -8.0%)\nSelling, general and administrative expenses: 656 (YoY +14.9%)\nOperating income: 1,113 (YoY -17.7%)\nOrdinary income: 1,142 (YoY -14.8%)\nNet income attributable to owners of parent: 777 (YoY -12.8%)","jir_category":"","jir_hashtags":"#KOASHOJIHOLDINGS, #Earnings, #Pharmaceuticals, #API, #ZaoNo2Factory","jir_key_figures":"Net sales: 5,771 million yen (YoY -3.0%)\nOperating income: 1,113 million yen (YoY -17.7%)\nNet income attributable to owners of parent: 777 million yen (YoY -12.8%)","jir_meta_title":"Koa Shoji Holdings Supplementary Financial Materials | Q1 FY2027","jir_meta_description":"Analysis of Koa Shoji Holdings' Q1 FY2027 supplementary financial materials: summary of net sales, operating income, segment trends, and outlook.","jir_og_title":"Koa Shoji Holdings Supplementary Financial Materials | Q1 FY2027","jir_og_description":"Key points from Koa Shoji Holdings' Q1 financial results: sales and profit trends, segment performance, and outlook.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":57021,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-142647","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n